SBS says it is backing Capricor investors in proposed securities class action

By Atlas Watchline Staff · Legal · August 21, 2026

Schall, Brown & Schwartz LLP said it is reminding investors about a proposed securities class action against Capricor Therapeutics over alleged misleading statements tied to Deramiocel data analysis and a BLA resubmission.

Schall, Brown & Schwartz LLP said it is reminding investors about a proposed securities class action against Capricor Therapeutics over alleged misleading statements tied to Deramiocel data analysis and a BLA resubmission.

Schall, Brown & Schwartz LLP said in an Aug. 21, 2026 press release that it is reminding investors about a class action lawsuit against Capricor Therapeutics Inc. The firm said the case concerns alleged violations of Section 10(b), Section 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.

The firm said it is seeking investors who bought Capricor shares during the proposed class period of Dec. 17, 2025 through July 26, 2026. Shareholders may contact the firm about possible lead plaintiff appointment, but lead plaintiff status is not required to recover and the class has not yet been certified.

According to the complaint summarized in the release, Capricor allegedly made false and misleading statements to the market. The notice says the company changed the statistical analysis plan used for clinical data related to Deramiocel even though the FDA had not agreed to changes from the pre-specified plan before the company resubmitted its Biologics License Application.

The release said Capricor faced a risk that the FDA would not approve the BLA for Deramiocel because of a lack of sufficient evidence of effectiveness. It also said investors suffered damages when the market learned the truth, though the press release did not provide further detail in the summary supplied here.

The press release identified Schall, Brown & Schwartz as a national shareholder rights litigation firm and listed Brian Schall and David Schwartz as contacts in Los Angeles. It gave the firm’s office address as 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, and included a phone number, website and email address.

The release said it may be considered attorney advertising in some jurisdictions. The press release was published on PR Newswire on Aug. 21, 2026.

What happens next depends on whether investors contact the firm and how the case proceeds in court. The notice does not say when a hearing or other court action is scheduled.

Sources

• PR Newswire: CAPR investors have opportunity to lead Capricor Therapeutics securities fraud lawsuit with SBS Law

Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.

This is the AMP version of the article. Read the full article on Atlas Watchline.